Amyotrophic lateral sclerosis: Current practice and future treatments

Current Opinion in Neurology

Volumn 23, Issue 5, 2010, Pages 524-529

  Bedlack, Richard S ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

amyotrophic lateral sclerosis; patient care; research

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ARIMOCLOMOL; BIOLOGICAL MARKER; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CEFTRIAXONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CK 2017357; DEXTROMETHORPHAN; ETIRACETAM; EXCITATORY AMINO ACID TRANSPORTER 2; HIGH DENSITY LIPOPROTEIN; KNS 760704; LOW DENSITY LIPOPROTEIN; MICRORNA; PRAMIPEXOLE; QUINIDINE; RILUZOLE; TALAMPANEL; UNCLASSIFIED DRUG;

AERATION; AMPLIFIER; AMYOTROPHIC LATERAL SCLEROSIS; ANTISENSE THERAPY; ANXIETY; ARTERIAL GAS; ARTIFICIAL VENTILATION; BEHAVIOR DISORDER; BRAIN COMPUTER INTERFACE; CLINICAL PRACTICE; COGNITIVE DEFECT; DEPRESSION; DIAPHRAGMATIC PACER; FATIGUE; FORCED VITAL CAPACITY; GASTROSTOMY; HUMAN; INSOMNIA; MEDICAL RESEARCH; MOTONEURON; OXIMETRY; PATIENT CARE; PSEUDOBULBAR PALSY; REVIEW; SCREENING TEST; STEM CELL TRANSPLANTATION; SURVIVAL TIME;

AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; COGNITION DISORDERS; EVIDENCE-BASED MEDICINE; FORECASTING; HUMANS; NEUROPROTECTIVE AGENTS; PALLIATIVE CARE; RILUZOLE; SURVIVAL RATE;

EID: 77956395029     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32833c7ac2     Document Type: Review

References (65)

1. Shook S, Pioro E. Racing against the clock: recognizing, differentiating, diagnosis and referring the amyotrophic lateral sclerosis patient. Ann Neurol 2009; 65:S10-S16.
2. Driver-Dunckley E, Hoxworth J, Patel N, et al. Superficial siderosis mimicking amyotrophic lateral sclerosis. J Clin Neuromuscul Dis 2010; 11:137-144.
3. Loustau V, Foltz V, Poulain C, et al. Diagnosis of amyotrophic lateral sclerosis in a patient treated with TNF alpha blockers for ankylosing spondylitis; fortuitous association or new side effect of TNF alpha blockers? Joint Bone Spine 2009; 76:213-214.
4. Strauss M, Koehler K, Krumbholz M, et al. Triple A syndrome mimicking ALS. Amyotroph Lateral Scler 2008; 9:315-317.
5. Chen IH, Mitsumoto H, Vonsattel J, Hays A. Amyotrophic lateral sclerosis and neurosarcoidosis: a case report. Muscle Nerve 2009; 39:234-238.
6. Kraemer M, Buerger M, Berlit P. Diagnostic problems and delay of diagnosis in amyotrophic lateral sclerosis. Clin Neurol Neurosurg 2010; 112:103-105.
7. Qureshi M, Bedlack RS, Cudkowicz M. Lyme disease serology in amyotrophic lateral sclerosis. Muscle Nerve 2009; 40:626-628.
8. DeCarvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for the diagnosis of ALS. Clin Neurophys 2008; 119:497-503.
9. DeCarvalho M, Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler 2009; 10:53-57.
10. Talbot K. Another gene for ALS: mutations in sporadic cases and the rare variant hypothesis. Neurology 2009; 73:1172-1173.
11. Cox LE, Ferraiuolo L, Goodall EF, et al. Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis. PLoS One 2010; 5:e9872.
12. Maruyama H, Morino H, Ito H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010; 465:223-226.
13. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive impairment (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2009; 73:1227-1233.
14. Woolley SC, York MK, Moore DH, et al. Detecting frontotemporal dysfunction in ALS: utility of the ALS cognitive behavioral screen (ALS-CBS). Amyotroph Lateral Scler 2010; 11:303-311.
15. Oskarsson B, Quan D, Rollins Y, et al. Using the Frontal Assessment Battery to identify executive functional impairments in amyotrophic lateral sclerosis: a preliminary experience. Amyotroph Lateral Scler 2010; 11:244-247.
16. Witgert M, Salamone AR, Strutt AM, et al. Frontal-lobe mediated behavioral dysfunction in amyotrophic lateral sclerosis. Eur J Neurol 2010; 1:103-110.
17. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional and respiratory therapies (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2009; 73:1218-1226.
18. Groeneveld GJ, van Kan HJ, Lie-A-Huen L, et al. An association study of riluzole serum concentration and survival and disease progression in patients with ALS. Clin Pharmacol Ther 2008; 83:718-722.
19. Bond ML, Craparo EF, Giammona G, Drago F. Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution. Nanomedicine (Lond) 2010; 5:25-32.
20. Cheah BC, Vucic S, Krishnan AV, Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem 2010; 17:1942-1959.
21. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2008; 105:2052-2057.
22. Aggarwal S, Zinman L, Simpson E, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9:481-488.
23. Orrell RW, Lane RJ, Ross M. A systematic review of antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Amyotroph Lateral Scler 2008; 9:195-211.
24. Pastula D, Moore D, Bedlack RS. Creatine for amyotrophic lateral sclerosis [a Cochrane review]. Cochrane Database Syst Rev (in press).
25. van der Steen I, van den Berg JP, Buskens E, et al. The costs of amyotrophic lateral sclerosis, according to type of care. Amyotroph Lateral Scler 2009; 10:27-34.
26. Vitacca M, Comini L, Tentorio M, et al. A pilot trial of telemedicine-assisted, integrated care for patients with advanced amyotrophic lateral sclerosis and their caregivers. J Telemed Telecare 2010; 16:83-88.
27. Spataro R, LoRe M, Piccoli T, et al. Causes and place of death in Italian patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2010 [Epub ahead of print].
28. Tollfsen E, Midgren B, Bakke P, Fondenes O. Amyotrophic lateral sclerosis: gender differences in the use of mechanical ventilation. Eur J Neurol 2010 [Epub ahead of print].
29. Ritsma BR, Berger MJ, Charland DA, et al. NIPPV: prevalence, approach and barriers to use at Canadian ALS centres. Can J Neurol Sci 2010; 37:54-60.
30. Park J, Kang S. Percutaneous radiologic gastrostomy in patients with amyotrophic lateral sclerosis on noninvasive ventilation. Arch Phys Med Rehabil 2009; 90:1026-1029.
31. Blondet A, Lebigot J, Nicolas G, et al. Radiologic versus endoscopic placement of percutaneous gastrostomy in amyotrophic lateral sclerosis: multivariate analysis of tolerance, efficacy and survival. J Vasc Interv Radiol 2010; 21:527-533.
32. Sorensen HT, Lash TL. Statins and amyotrophic lateral sclerosis: the level of evidence for an association. J Intern Med 2009; 266:520-526.
33. Zinman L, Sadeghi R, Gawel M, et al. Are statin medications safe in patients with ALS? Amyotroph Lateral Scler 2008; 9:223-228.
34. Drory V, Bronipolsky T, Artamonov L, Nefussy B. Influence of statins treatment on survival in patients with amyotrophic lateral sclerosis. J Neurol Sci 2008; 273:81-83.
35. Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008; 70:100-109.
36. Gilio F, lacovelli E, Frasca V, et al. Botulinum toxin A for the treatment of sialorrhea in amyotrophic lateral sclerosis: a clinical and neurophysiological study. Amyotroph Lateral Scler 2010; 11:359-363.
37. Jackson CE, Gronseth G, Rosenfeld J, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009; 39:137-143.
38. Olney N, Rosen H. Avp-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain. IDrugs 2010; 13:254-265.
39. Cohen S, Elackattu A, Noordzij J, et al. Palliative treatment of dysphonia and dysarthria. Otolaryngol Clin North Am 2009; 42:107-121.
40. Dalbello-Haas V, Florence JM, Krivickas LS. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev 2008:CD005229.
41. Cheah B, Boland R, Brodaty N, et al. Inspirational-inspiratory muscle training in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009; 10:384-392.
42. Katzberg H, Khan A, So Y. Assessment: symptomatic treatment for muscle cramps (an evidence-based review). Neurology 2010; 74:691-696.
43. Bedlack RS, Pastula DM, Hawes J, Heydt D. Open label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron diseases. Amyotroph Lateral Scler 2009; 10:210-215.
44. Pascuzzi R, Shefner J, Chappell A, et al. A phase 2 trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010; 11:266-271.
45. Gribkoff V, Bozik M. KNS-760704 for the treatment of amyotrophic lateral sclerosis. CNS Neurosci Ther 2008; 14:215-226.
46. Lanka V, Wieland S, Barber J, Cudkowicz M. Arimoclomol: a potential therapy under development for ALS. Expert Opin Investig Drugs 2009; 18:1907-1918.
47. LLieva H, Polymenidou M, Cleveland D. Noncell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 2009; 187:761-772.
48. Lee SG, Su ZZ, Emdad L, et al. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem 2008; 283:13116-13123.
49. Russell A, Lee K, Jia Z, et al. The fast skeletal troponin activator, CK-20117357, increases skeletal muscle force in vitro and in situ. 2009 Experimental Biology Conference; New Orleans, LA; April 2009. Poster presentation.
50. Zhong Z, Ilieva H, Hallagan L, et al. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglial cells. J Clin Invest 2009; 119:3437-3449.
51. Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006; 116:2290-2296.
52. Williams A, Valdez G, Moresi V, et al. MicroRNA 206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 2009; 326:1549.
53. Papadeas S, Maragakis N. Advances in stem cell research for amyotrophic lateral sclerosis. Curr Opin Biotechnol 2009; 20:545-551.
54. Onders RP, Elmo M, Khansarinia S, Bowman B. Complete worldwide operative experience in laparoscopic diaphragm pacing: results and differences in spinal cord injured patients and amyotrophic lateral sclerosis patients. Surg Endosc 2009; 23:1433-1440.
55. Bai O, Lin P, Huang D, et al. Towards a user-friendly brain-computer interface: initial tests in ALS and PLS patients. Clin Neurophysiol 2010 [Epub ahead of print].
56. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and human ALS. Neurobiol Dis 2007; 26:1-13.
57. Beleza-Meireles A, Al-Chalabi A. Genetic studies of amyotrophic lateral sclerosis: controversies and perspectives. Amyotroph Lateral Scler 2009; 10:1-14.
58. Scott S, Kranz J, Cole J, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 2008; 9:4-15.
59. Wegorzewska I, Bell S, Cairns N, et al. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 2009; 106:18809-18814.
60. Turner M, Kiernan M, Leigh P, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 2009; 8:94-109.
61. Cudkowicz M, Katz J, Moore D, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010; 11:259-265.
62. Bedlack RS, Pastula DM, Welsh E, et al. Scrutinizing enrollment in ALS clinical trials: room for improvement? Amyotroph Lateral Scler 2008; 9:257-265.
63. Bedlack RS, Wicks P, Heywood J, Kasarskis E. Modifiable barriers to enrollment in American ALS research studies. Amyotroph Lateral Scler 2010 [Epub ahead of print].
64. Allison M. Can web 2.0 reboot clinical trials? Nat Biotechnol 2009; 27:895-902.
65. Quereshi M, Schoenfeld D, Paliwal Y, et al. The natural history of ALS is changing: improved survival. Amyotroph Lateral Scler 2009; 10:324-331.